




**The Paradigm Changing Developments  
in Lymphoma Come to Life**

**1 - 4 APRIL 2021**  
**Jeddah, KSA**



SAUDI LYMPHOMA GROUP  
الجمعية السعودية لأورام الليمفاوية





# CONTENTS

»» Cover	»» Page 1
»» Contents	»» Page 2
»» Chairman's Message	»» Page 3
»» Chairman , Organizing Committee,Scientific Committee	»» Page 4
»» Speakers	»» Page 5
»» Chairpersons	»» Page 21
»» Scientific Program	»» Page 22
»» Sponsors	»» Page 24

## CHAIRMAN'S MESSAGE

As the Conference Chairman, it is with immense pleasure and honor to welcome everyone to the 3<sup>rd</sup> International Lymphoma Conference with the theme “The Paradigm Changing Developments in Lymphoma Come to Life” on 1 - 4 April 2021 at Jeddah, Kingdom of Saudi Arabia. This four-day event is virtually conducted using an amazing online platform set-up where it brings everyone into a real face-to-face experience.

In the midst of the current global situation, the 3<sup>rd</sup> International Lymphoma Conference is maximizing and taking an advantage of utilizing the virtual powerful tool to continually connect to the people delivering updated information and highly knowledgeable insights in the field of lymphoma. Accordingly, this is our third-year assembly since its inception in 2018 and it is so rewarding to see the growth of this conference. As always, this year's conference is likely to provide distinctive levels of experiences; thus, it will bring a learning experience through a very strong and thought-provoking program; also an interacting experience wherein it gives a greater opportunity to form productive collaborations with like-minded healthcare professionals; and a motivational experience as distinguished international speakers will surely unveil their knowledge in regard to the latest innovations and comprehensive overview of the up-to-date research developments in lymphoma.

The Organizing and Scientific Committees are truly convinced that attendees from national and international setting will be inspired by the presentations and talks constituting in this year's program. Furthermore, they will be engaged in sharing thoughts as well as exchanging of ideas on how to chart and forward to reach new heights towards how the lymphoma is studied and practiced in association with the current and future research developments and directions.

As the Chairman of the ILC 2021, I would like to thank all of the conference participants for their contributions which are the foundation of this conference. I am glad to personally meet and warmly welcome all of you and sincerely hope you enjoy this fruitful and meaningful conference.



**Dr. Mubarak Al Mansour**  
Conference Chairman



**DR. MUBARAK AL MANSOUR**

**Conference Chairman**

Section Head & Consultant, Adult Medical Oncology  
Oncology Department, Princess Noorah Oncology Center, King Abdulaziz Medical City  
Ministry of National Guard Health Affairs – WR  
Associate Dean, Academic & Student Affairs | Associate Professor, Medical Oncology  
College of Medicine – Jeddah, King Saud Bin Abdulaziz University For Health Sciences

**ORGANIZING COMMITTEE**



**MS. JACKIELYN CUENCA ALTURAS**

**Conference Coordinator**

Administrative Assistant I  
Office of the Associate Dean, Academic & Student Affairs  
College of Medicine - Jeddah, KSAU-HS



**MS. NAJWA HAMAD**

**Manager, Symposia & Conferences**

Deanship of Postgraduate Education - Jeddah, KSAU-HS

**SCIENTIFIC COMMITTEE**



**DR. AHMAD ALSAEED**

Deputy Director, Oncology Center  
King Abdulaziz Medical City, MNGHA WR



**DR. AHMED ABSI**

Consultant, Adult Hematology/BMT, Oncology Center  
King Abdulaziz Medical City – MNGHA WR



**DR. IHAB AL-HEMAIDI**

Section Head, Adult Hematology  
BMT, Oncology Center  
King Abdulaziz Medical City – MNGHA WR



**DR. MAJED AL AHMADI**

Consultant, Adult Hematology/BMT, Oncology Center  
King Abdulaziz Medical City – MNGHA WR

## SPEAKER



**STEPHEN M. ANSELL, M.D., Ph.D**



Stephen M. Ansell, M.D., Ph.D. is a Consultant in the Division of Hematology, Department of Internal Medicine at Mayo Clinic in Minnesota. Dr. Ansell currently serves as Chair of the Mayo Clinic Lymphoma Disease-Oriented Group and Chair of Faculty Development and Recruitment for the Division of Hematology. He joined the staff of Mayo Clinic in 1999 and holds the academic rank of Professor of Medicine, Mayo Clinic Alix School of Medicine.

Dr. Ansell earned his M.B., Ch.B., and Ph.D. degrees at the University of Pretoria in Pretoria, South Africa, where he also completed an internship in Internal Medicine and Surgery, a residency in Internal Medicine, and a Fellowship in Medical Oncology. Dr. Ansell continued his education at University of the Witwatersrand in Johannesburg where he was a Registrar in Internal Medicine. He then came to the United States and completed a residency in Internal Medicine and then a Fellowship in Hematology/Oncology at Mayo Clinic.

Dr. Ansell's research focuses on investigating the phenotype and activity of intratumoral T cells and developing strategies to modulate the T-cell infiltration in B-cell lymphoma. Further areas of research interest include the development of biologic therapies for non-Hodgkin's lymphoma, Hodgkin's disease and Waldenstrom macroglobulinemia. The current strategies being developed include the use of novel antibodies and cytokines, the use of targeted therapies, and the development of strategies to inhibit signaling through receptors that promote the survival of malignant B cells. The utility of these strategies is being tested in early-phase clinical trials. Dr. Ansell is frequently invited to give presentations on his research to both national and international audiences, and has published in high-impact scientific journals. He is associate editor of the American Journal of Hematology and serves on the Editorial Board for Blood, Blood Cancer Journal, JAMA Oncology and Journal of Clinical Oncology. He is often a reviewer for various scientific journals. In recognition of his work, Dr. Ansell has received awards and honors, including the New Investigator Award, the Teacher of the Year Award in the Hematology Fellowship Program, and the Department of Medicine Research Award for Landmark Contributions to the Literature.

In addition to his research activities, Dr. Ansell is active in education and mentoring. He holds full faculty privileges in Biomedical Engineering at Mayo Clinic Graduate School of Biomedical Sciences. Dr. Ansell also serves on the Scientific Advisory Board of the Leukemia & Lymphoma Society (LLS), the Lymphoma Research Foundation (LRF) and the International Waldenstrom Macroglobulinemia Foundation (IWMF)

## SPEAKER



JOSEPH MICHAEL CONNORS, M.D.



Joseph M. Connors, M.D. is a Clinical Professor Emeritus in the Department of Medicine, Division of Medical Oncology, at the University of British Columbia and past Clinical Director of the BC Cancer Centre for Lymphoid Cancer from 1989 to 2018.

Dr. Connors obtained his medical degree at Yale University, trained in internal medicine at the University of North Carolina in Chapel Hill, and completed his medical oncology fellowship with Dr. Saul Rosenberg at the Stanford University Medical Center from 1979 to 1981. He then joined the staff and faculty at BC Cancer and the University of British Columbia and has focused his clinical activities and research efforts in the area of lymphoid cancers, and most recently, on the application of genomic analysis to understanding and optimizing treatment for these diseases.

Dr. Connors is best known for his clinical investigations into the biology and treatment of Hodgkin lymphoma, non-Hodgkin lymphoma, chronic lymphocytic leukemias and myeloma. He previously served as a member of the executive committee of the Hematology Site Group for the NCIC Clinical Trials Group, on the scientific advisory board of the Lymphoma Foundation Canada and on the organizing committee of the International Conference on Malignant Lymphoma. He is a current member of the organizing committee of the International Symposium on Hodgkin Lymphoma.

Dr. Connors has published over 400 peer-reviewed scientific articles addressing various aspects of research into lymphoid cancers. He has been awarded the Terry Fox Cancer Research Award by the British Columbia Medical Association (twice, 1983 and 2018); the Bernard L. Schwartz Memorial Award from Scripps Health, San Diego; the Canadian Cancer Society John W. Whittick Memorial Award from the Saskatchewan Medical Association; the Karl Musshoff lifetime achievement Award from the German Hodgkin Lymphoma Study Group; the Maria Ricci Award for translational research from Queens University and the NCIC Clinical Trials Group; the Hayne-Langley Award for translational research for hematologic diseases from Dalhousie University; the 2013 Dr. Don Rix Award for Lifetime Achievement from LifeSciences BC; the John Ultmann Award at the International Conference on Malignant Lymphoma; and a Canadian Medical Association Lifetime Achievement Award and has been recognized as one of the 20 most influential scientific minds in Canada, in The World's Most Influential Scientific Minds, Thomson Reuters, Inc. every year since the list was initiated in 2014.



## SPEAKER



ANDREW JOHN DAVIES, M.D.,



Andrew John Davies is a Professor of Hematological Oncology in the Cancer Sciences Unit, Faculty of Medicine, at the University Hospital Southampton, United Kingdom.

He completed his training in Medical Oncology at St Bartholomew's Hospital in London, and as a Cancer Research UK clinical fellow he undertook a PhD examining the molecular mechanisms underlying transformation of follicular lymphoma to more aggressive histological sub-types.

Prof. Davies is the past Chair of the UK National Cancer Research Institute High Grade Lymphoma Study Group and Director of Cancer Research UK/National Institute of Health Southampton Experimental Cancer Medicine Centre. He is also the Wessex Regional Lead for cancers in Teenagers and Young Adults.

Prof. Davies specializes in the treatment of malignant lymphoma and the use of high-dose chemotherapy. He has a particular interest in the investigation of monoclonal antibody-containing therapies applied to lymphoma and also in the translation of biomarkers and novel therapies to the clinical arena. He has extensive experience in early phase trials, including leading several first in man lymphoma studies.

## SPEAKER



**ANDRÉS JOSÉ MARÍA FERRERI, M.D.**

Andrés José María Ferreri, MD, is the Director of the Lymphoma Unit, Department of Oncology and the Deputy Director of the Division of Onco-Hematological Medicine, Department of Onco-Hematology, San Raffaele Scientific Institute, Milano, Italy. Also, he is a Contract Professor in Hematology, and Oncology – International MD Program, and Contract Professor in Oncology – Dental School, Course Director of Oncology - International MD Program, and Teaching Assistant in Hematology and Oncology– School of Medicine at the Università Vita e Salute, San Raffaele Scientific Institute, Milano. Likewise, Dr. Ferreri, Faculty of the University Master on Diagnosis and treatment of patients with lymphoma, University of Udine, Udine, Italy, and a Lecturer in the Certificate of Competence in Lymphoma at the European School of Oncology and Ulm University.

Dr. Ferreri graduated in Medicine and Surgery at the University of Buenos Aires (1985); moved to Italy in 1989, obtained the second degree in Medicine and Surgery at the University of Parma in 1992, and the second specialization in Medical Oncology at the University of Milan in 2005.

Dr. Ferreri has been a founder of the International Extranodal Lymphoma Study Group and the Italian Lymphoma Foundation. He is a member of numerous international scientific societies and is faculty of the European School of Oncology. He is author of numerous scientific articles and chapters of books in English, Italian and Spanish, wherein 332 abstracts selected for presentation in National and International scientific meetings, 319 original papers and reviews published in peer reviewed scientific journals (Scopus), H-index: 64, and 23 chapters of book and web sites, written in English, Italian and Spanish.

Dr. Ferreri scientific skills include laboratory, translational and clinical research studies on lymphomas at IRCCS Ospedale San Raffaele. He has conducted numerous studies on different extranodal lymphomas and is an indisputable authority in the area of brain lymphoma, having defined the treatment guidelines applied in all countries. His studies have the merit of seeking tumor causes and using them as therapeutic targets, particularly in the field of lymphomas associated with infectious agents.



SPEAKER



John G. Gribben, M.D., Ph.D.



Prof. Gribben holds the Gordon Hamilton Fairley Chair of Medical Oncology at St. Bartholomew's Hospital, Barts Cancer Institute, Queen Mary, University of London. His doctoral studies were performed at University College London as the recipient of a Wellcome Trust Fellowship Award. He continued post-doctoral training with Professor Lee Nadler at the Dana-Farber Cancer Institute, Harvard Medical School.

In 1992, Prof. Gribben was appointed to the Faculty at Harvard Medical School, where he remained as Associate Professor of Medicine and an Attending Physician at the Dana-Farber Cancer Institute and Brigham and Women's Hospital, until returning to London in 2005. Prof. Gribben is a founding member of the CLL Research Consortium, Associate Editor of Blood and was elected a Fellow of the Academy of Medical Science.

Prof. Gribben's primary research interests include the immunotherapy of cancer (including stem cell transplantation), the identification of B-cell-tumour antigens; and the detection and treatment of minimal residual disease in leukaemia and lymphoma.

Professor John Gribben graduated in medicine from the University of Glasgow in 1980. He was a doctoral fellow at University College London and in Medical Oncology at the Dana-Farber Cancer Institute, Harvard Medical School. He remained on the faculty for at Harvard Medical School 17 years before returning to the UK in 2005. He specializes in hematological cancers including lymphomas, leukemias and bone marrow transplantation and immunotherapy approaches including CAR-T cells. He holds the Hamilton Fairley Chair of Medical Oncology at Barts and the London School of Medicine, Queen Mary, University of London and his NHS post is as Honorary Consultant Medical Oncologist Barts and The London NHS Trust. He is the author of more than 500 articles and chapters in peer-reviewed publications and has a global reputation for his work in researching new drugs and forms of cancer treatment and the role of immunotherapy in cancer. He has grant funding from The National Cancer Institute, Cancer Research UK, Wellcome Trust and the Medical Research Council for pioneering studies in leukaemia and lymphoma. He takes up his role as President of the European Hematology Association (EHA) for 2 years from June 2019 is currently serves on the EHA Executive Board. He is Chair of the international workshop for non-Hodgkin's lymphoma (iwNHL) and co-chair of the international workshop for CAR T cells (iwCART). He was an Editor of Blood from 2007-2014. He is a on the Board of Trustees of the London Clinic.

## SPEAKER



STEVEN MICHAEL HORWITZ, M.D.



Steven Michael Horwitz, M.D., is an Attending Physician at the Memorial Hospital for Cancer and Allied Diseases in New York., and a member at the Memorial Sloan Kettering Cancer Center, Department of Medicine. He is also an Associate Professor of Medicine at the Weill Cornell Medical College, New York, New York, United States.

Dr. Horwitz completed his Medicine Degree at Case Western Reserve University, School of Medicine, Cleveland, Ohio in 1993. He took his Internship in 1993-1994 and Residency in 1994 - 1996 at the University of Rochester Medical Center Strong Memorial Hospital Rochester, New York, United States. While he obtained his Fellowship in 1997 – 2001 and Assistant Fellowship/ Program Director 2000 – 2001 at the Stanford University School of Medicine Stanford, California, United States.

Dr. Horwitz is a Medical Oncologist who focuses on the care of patients with lymphoma, and has clinical expertise in all types of lymphomas. Furthermore, Dr. Horwitz was engaged in mentorship since 2010 and served as the Mentor at several projects in MSK Medical Oncology/ Hematology Clinical Fellow and awarded as Conquer Cancer Foundation/ American Society of Clinical Oncology (ASCO) Young Investigator's Award in 2016 for the Project titled Microbiota in autologous stem cell transplant (co- mentor with Marcel van den Brink, MD, PhD). He is also active in the clinical teaching for Lymphoma Outpatient Clinic (fellows, residents, students), 2 day/week and Lymphoma Inpatient Rounds (fellows, residents, students) 4-6 weeks/year since 2001. Moreover, Dr. Horwitz research is aimed at developing an improved understanding of new and potentially more effective therapies for patients with several less-common types of lymphoma, including T cell lymphomas, cutaneous (skin) lymphomas, Hodgkin disease, and lymphomas in immunosuppressed patients after organ transplant (post-transplant lymphoproliferative disorders or PTLT). He has been instrumental in leading or co-leading the development of and expanding clinical indications for a number of new therapies for T-cell lymphomas.

## SPEAKER



**BRAD KHAL, M.D.**



Brad Kahl, MD, is a Professor of Medicine and Director of the Lymphoma Program at Washington University School of Medicine, St. Louis. He earned his Medical Degree from Tufts University School of Medicine, Boston. He then completed a Residency in Internal Medicine, a year as Chief Resident, and a Fellowship in Hematology at the University of Wisconsin (UW).

Dr. Kahl's research focuses on improving outcomes for patients with lymphoma through testing novel agents in well-designed clinical trials. He is Chair of the ECOG-ACRIN lymphoma committee since 2009 where he has facilitated the development of multiple large clinical trials. He helped successfully renew an ECOG scientific operations grant, and led a successful effort to obtain a National Clinical Trials Network Lead Academic Performance Site award for UW. He is the Washington University principal investigator for the LEO consortium, a large molecular epidemiology effort funded by the NCI.

Dr. Kahl is a member of several professional societies, including the American Society of Hematology, American Society of Clinical Oncology, ECOG-ACRIN, US Food and Drug Administration Oncologic Drugs Advisory Committee, and the National Cancer Institute Lymphoma Steering Committee. He is a member of the Lymphoma Research Foundation Scientific Advisory Board and served as Chair of the LRF Mantle Cell Lymphoma Consortium from 2012-2018. He is a member of NCCN panel which established recommendations and guidelines in Chronic Lymphocytic Leukemia.

**SPEAKER****DAVID GEORGE MALONEY, M.D., Ph.D.**

David George Maloney is a Professor of Medicine, Division of Oncology, University of Washington, Seattle, WA, USA. In 1994- 2000, he was an Assistant Member at Fred Hutchinson Cancer Research Center, Seattle, WA, but in 2000 - June 2009 he became as an Associate Member, and finally a Member in July 2009. He served as an Assistant Professor of Medicine from 1995 to 2001 at the Division of Oncology, University of Washington, Seattle, WA; promoted into Associate Professor in 2001 to June 2010, and eventually, upheld as Professor of Medicine in July 2010 until present.

Prof. Maloney finished his BS in Chemistry/Biochemistry, Whitworth College, Spokane, Washington in 1973-1977. He obtained his M.D in 1978-1985, and attained his Ph.D., in 1991 at Stanford University, Stanford, California, respectively. He had his Postgraduate Trainings in 1985-1988 as Internship and Residency in Internal Medicine, Brigham and Woman's Hospital, at Boston, MA and 1988-1994 as Fellow in Oncology, at Stanford University Medical Center, Stanford, CA. Prof. Maloney received his Board Certification in Internal Medicine in 1988 and in Medical Oncology in 1991. He has several hospital appointments and faculty positions.

Prof. Maloney was became the Leonard and Norma Klorfine Endowed Chair for Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA in May 2016 'till present. Moreover, since January 2016, Prof. Maloney is the Medical Director of Cellular Immunotherapy, at Fred Hutchinson Cancer Research Center, Seattle, WA; and since June 2016, he is the Service Medical Director of Cellular Immunotherapy and Bezos Family Immunotherapy Clinic, Seattle Cancer Care Alliance, Seattle, WA. Furthermore, for Prof. Maloney's hospital appointments, in 1994-2001 he was an Attending Physician, at Swedish Medical Center, Seattle, WA. In 1994-199, an Attending Physician, at Fred Hutchinson Cancer Research Center, Seattle, WA; while in 1995 until present, he is an Attending Physician, at the University of Washington Hospital, Seattle, WA; and in 2001 'till date, he is an Attending Physician, at Seattle Cancer Care Alliance, Seattle, WA.

He is a member of several Professional Organizations since 1992 and until present. He is extremely involves in local, national, and international membership with responsibilities as a member, co-chair, and chair of different committees, programs, centers, and institutions. For his Editorial Responsibilities: BioOncology Watch in 1999-2005, Clinical Lymphoma Journal in 2000 until present, and Journal of Clinical Oncology in 2002 to 2004. Likewise, Prof. Maloney received a number of awards since 1990 as Young Investigator Travel Award, ASH and the latest from 2016-2017 as the America's Top Doctors® for Cancer, Top Doctor – Medical Oncology, 2016 & 2017 Seattle Magazine. In addition, he has numerous of Manuscripts in Refereed Journals, Book Chapters, and Other Publications.

## SPEAKER



**CRAIG MOSKOWITZ, M.D.**



Craig Moskowitz is a Physician-In-Chief in the Sylvester Comprehensive Cancer Center since 2018, where he is responsible for the development, implementation and administration of high quality, value-based oncology care through all of Sylvester's facilities. Prior to joining Sylvester, Dr. Moskowitz was at Memorial Sloan Kettering since 1995. He became a Member of Memorial Sloan Kettering in 2011 and received the Steven A. Greenberg Chair in Lymphoma Research in 2014.

Dr. Moskowitz received his M.D. degree at Wayne State University School of Medicine. He completed an Internal Medicine Internship and Residency at Jacobi Hospital, affiliated with Albert Einstein College of Medicine, and a Fellowship in Hematology Oncology at the Memorial Sloan Kettering Cancer Center. He is a Board Certified in Internal Medicine, Medical Oncology and Hematology.

Dr. Craig Moskowitz' research has focused on improving the outcome of patients with poor risk Hodgkin Lymphoma (HL) and Diffuse Large B Cell Lymphoma (DLBCL). This effort has been conducted along two tracks: 1) optimizing therapy for patients with relapsed and refractory disease, including high dose therapy (HDT) and autologous stem cell transplant (ASCT) and studying new agents that can be incorporated into salvage therapy, and 2) developing risk-adapted strategies to optimize the treatment of newly diagnosed DLBCL and Hodgkin's Lymphoma by using what we have learned in the relapsed and refractory setting. This research has led to changes in standard of care that include PET-adapted therapies, maintenance therapy post-ASCT, utility of clinical and molecular-derived prognostic models in the relapsed and refractory setting, and the incorporation of novel immune-based approaches in the second-line setting. Two agents were approved during these clinical investigations: Brentuximab Vedotin for maintenance therapy post-ASCT for Hodgkin Lymphoma and Pembrolizumab for palliation of poor risk Hodgkin Lymphoma.

## SPEAKER



**GRZEGORZ S. NOWAKOWSKI, M.D.**



Grzegorz (Greg) Nowakowski, M.D., is a consultant and an Associate Professor of Medicine and Oncology, Division of Hematology at Mayo Clinic in Rochester, Minnesota, where he also serves as the Aggressive Lymphoma Program Director, the Chair of Education and an Advanced Hematology Fellowship Program Director.

Dr. Nowakowski received his MD from the Medical University of Warsaw, Poland. He completed his internal medicine residency at Yale University Medical School - Norwalk Hospital, Norwalk, Connecticut and his fellowship in Hematology and Medical Oncology at Mayo Clinic, Rochester, Minnesota. Dr. Nowakowski joined the Mayo Clinic Lymphoma Group in 2006 as a Mayo Foundation Scholar. He is an alumnus of the American Society of Hematology (ASH) Clinical Research Training Institute and American Society of Clinical Oncology (ASCO) Leadership Development Program.

Dr. Nowakowski's research focuses on the molecular classification and biology of lymphoproliferative disorders, new approaches to clinical trial design and novel therapies for lymphoma and hematological disorders. He is an investigator in University of Iowa/Mayo Clinic Lymphoma Specialized Center of Research Excellence program, where he leads multiple projects on precision medicine and use of real-world data to support early drug development. Dr. Nowakowski has authored over 140 articles and numerous book chapters. Dr. Nowakowski serves as a principal investigator of multiple investigator-initiated and cooperative group clinical trials (ECOG, Alliance) and a member of ECOG Lymphoma Core Committee. Dr. Nowakowski also chairs the Lymphoma Committee and Hematological Malignancy Program in the Academic and Community Cancer Research United (ACCRU) network. He currently serves as member of ASH Taskforce on Molecular Hematology and co-chairs the ASH Working Group on Clinical Trial Innovation. He also serves as a member of the American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Award Selection Committee and the chair of ASCO Research Community Forum. Dr. Nowakowski served as Voting Member of the Oncology Drugs Advisory Committee (ODAC) to the Food and Drug Administration (FDA).



SPEAKER



OWEN O'CONNOR, MD, PhD



Owen S. O'Connor, M.D, Ph.D, is leading a T-cell Lymphoma Research Program at the University of Virginia where he runs a laboratory focused on PTCL and new drug discovery.

Prof. O'Connor graduated as Magna Cum Laude in B.S. Biology/Environmental taken at Manhattan College, Bronx, New York in 1982. He obtained his Ph.D. in Environmental Medicine with a specialty in chemical carcinogenesis and Awarded as Full Research Assistantship in 1990 at the School of Medicine, Institute of Environmental Medicine, New York University, New York. In 1994, he attained his Medical Doctorate at the University of Medicine & Dentistry of New Jersey (UMDNJ-RWJ), New Brunswick, N. J. He underwent Post-Doctoral Training as an Intern and Resident at Cornell University – The New York Hospital and as a Fellow in Hematology and Oncology and Pharmacology at Memorial Sloan Kettering Cancer Center.

Prof. O'Connor has held several professional positions and appointments: in 2000-2006 he was an Instructor at Joan and Sanford Weil Medical College of Cornell University Medical Center, The New York Presbyterian Hospital. He was an Assistant Attending Physician at the Department of Medicine and the Head of the Laboratory of Experimental Therapeutics for the Lymphoproliferative Malignancies, Division of Hematologic Oncology, Lymphoma & Developmental Chemotherapy Services, Memorial Sloan Kettering Cancer Center. He was named the Director of Lymphoid Development and Malignancy Program at Herbert Irving Comprehensive Cancer Center, Columbia University from 2006-2009. From 2009-2011, Prof. O'Connor was named Director, Division of Hematology and Medical Oncology, Deputy Cancer Center Director for Clinical Research and Cancer Treatment (NYU Cancer Institute), and Professor of Medicine and Pharmacology at the NYU Langone Medical Center New York. In 2011 was the Founding Director of Center for Lymphoid Malignancies, Department of Medicine; at New York Presbyterian Hospital – Columbia University Medical Center, College of Physicians and Surgeons, Columbia University. Most recently, he has accepted a role to lead a T-cell Lymphoma Research Program at the University of Virginia where he runs a laboratory focused on PTCL and new drug discovery.

Prof. O'Connor has earned numerous honors and awards in diverse areas over the years. Accordingly, he received the America's Top Doctors' Award consistently for 22 times from the period of 2011-2017. He was recognized in April 2016 as Top 1% in America's Most Honored Professionals and Distinguished Hess Professorship in 2018 at the University of Virginia, Emily Couric Clinical Cancer Center, Charlottesville, VA. In addition, he is the recipient of the American Cancer Society Research Professorship, the most prestigious award made by the Society. Prof. O'Connor also found the The Global T-Cell Lymphoma Consortium. He has published extensively with over 200 publications, and has edited the first textbook on T-Cell Lymphoma due to be released in April 2021 by Wiley Science.

## SPEAKER



**Laurie Sehn, MD, MPH**



Laurie Sehn, M.D, M.PH, is a Clinical Professor at the BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Canada. She has been a Medical Oncologist and Clinical Investigator at BC Cancer since 1998 and is currently the Chair of the Lymphoma Tumour Group.

Dr. Sehn finished her medical degree from McGill Medical School, Montreal, Canada and received her training in Internal Medicine at Columbia Presbyterian Medical Center, Columbia University, New York, USA. She was trained in Haematology-Oncology at Brigham and Women's Hospital and the Dana-Farber Cancer Institute, Harvard University, Boston, wherein she obtained her Masters of Public Health degree from Harvard School of Public Health, Harvard University. Prior returning to Canada, she spent a year as faculty at the Dana-Farber Cancer Institute with the Bone Marrow Transplantation service.

Dr. Sehn is a Chair of the Medical Advisory Board for the International Lymphoma Coalition. She has also served as a member of the editorial board of Journal of Clinical Oncology and Leukemia Lymphoma, and is currently an Associate Editor for Blood. Likewise, Dr. Sehn also serves as Co-Chair of the Lymphoma Site of the Canadian Cancer Trials Group as well as a Co-Chair of the Lunenburg Lymphoma Biomarker Consortium.

Dr. Sehn's research interests include population-based outcomes analyses, identification of prognostic factors and predictive biomarkers, and development of novel therapies in lymphoma.

## SPEAKER



**JULIE VOSE, M.D.**



Julie Vose, MD, MBA, is the Neumann M. and Mildred E. Harris Professor and Chief in the Division of Oncology/Hematology at the University of Nebraska Medical Center (UNMC) in Omaha, Nebraska.

Dr. Vose received her medical degree, completed her residency in Internal Medicine, served as Chief Resident, and completed a Fellowship in Hematology/Oncology at the University of Nebraska Medical Center. She also completed the MBA in Health Administration through the University of Colorado Business School in Denver.

Dr. Vose has focused her career on translational research for improvement in the therapy of non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) by developing a focused translational research program evaluating novel therapies such as monoclonal antibodies, vaccine and cellular therapies, pathway-directed agents, and stem cell transplantation. She has published extensively on improvements in therapy and transplantation research, which has added substantially to the research and knowledge base for the therapy of lymphoma. She was 2015/2016 president of the American Society of Clinical Oncology (ASCO).

## SPEAKER



MICHAEL WANG, MD



Michael Wang is a Professor in the Department of Lymphoma & Myeloma at the University of Texas, MD Anderson Cancer Center, Houston, Texas, USA. He is the current Director of Mantle Cell Lymphoma (MCL) Program of Excellence and Co-Director of Clinical Trials as well as the PI of the B-Cell Lymphoma Moon Shot Program at MD Anderson.

Dr. Wang obtained his M.D. from Shandong Medical University and M.S. from Beijing University, Medical School. He completed his clinical training as a resident at Norwalk Hospital, Norwalk, Conn., and as a Fellow in Oncology and in Hematology at MD Anderson.

Dr. Wang has published more than 150 peer-reviewed papers and have presented it in at meetings nationally and internationally. During the past 15 years, Dr. Wang have focused on preclinical and clinical research and established a MCL-SCID-hu mouse model, which is the first human primary MCL animal model for the study of the biology and treatment of MCL. His clinical research of the Bruton's tyrosine kinase inhibitor ibrutinib was published in the *New Eng. J. Med.* in 2013. Dr. Wang is currently acting as National PI of the multisite international phase 5 registration trial for ibrutinib in MCL.

SPEAKER



**MICHAEL WILLIAMS, M.D., Ph.D.**



Michael Williams, M.D., PhD. is the Byrd S. Leavell Professor of Medicine and Professor of Pathology and Physician Lead at Cancer Service Line, UVA Health. He is also an Associate Director for Clinical Affairs, UVA Cancer Center, University of Virginia School of Medicine, Charlottesville.

Dr. Williams received his MD from the University of Cincinnati College of Medicine and Master of Science from the Harvard School of Public Health. After completing Medicine residency, Chief Residency, and Fellowship at UVA Health he joined the Department of Medicine faculty and the NCI-designated Cancer Center. Over the years, he has served in several leadership roles including Chief, Hematology/Oncology Division.

Dr. Williams' patient care and research interests include clinical trials and translational science for mantle cell lymphoma, other non-Hodgkin lymphomas and CLL, with a focus on targeted agents and immuno-therapeutics. He serves on the Scientific Advisory Board and Executive Committee of the Lymphoma Research Foundation, and is a member of the Eastern Cooperative Oncology Group Lymphoma Core Committee and of the European Mantle Cell Lymphoma Network.

Dr. Williams is past Chair of the Hematology Subspecialty Board of the American Board of Internal Medicine, was a member of the ABIM Council, and currently serves on ABIM's Hematology Longitudinal Assessment Committee. He serves on the editorial board of the Journal of Clinical Oncology, is the Associate Editor for Lymphoma for ASCO cancer.net, and is Associate Editor for Hematologic Malignancies for the NEJM Group Journal Watch Oncology and Hematology. He participates regularly in national and international programs devoted to education and research in lymphoma and CLL.

## SPEAKER



**PIER LUIGI ZINZANI, M.D., Ph.D**



PierLuigi Zinzani, M.D., Ph.D, is an Associate Professor of Hematology and Chief of the Clinical and Translational Program of the Lymphoma Unit at the Institute of Hematology and Medical Oncology "L. & A. Seràgnoli" University of Bologna, Italy.

He graduated in Medicine and Surgery as with Honors in 1984 and obtained the Speciality in Hematology in 1987 also awarded as with honours at the University of Bologna. In 1989, he was awarded a "Post-Doctoral Fellowship in Medical Oncology" released by the "Roger Williams Cancer Center" of Providence (USA). He was a President of Italian Foundation on Lymphoma (FIL) from November 2013 to 2015 and currently, he is a member of the Board of Directors.

Prof. Zinzani is a member of the Italian Society of Hematology, the Italian Society of Experimental Hematology, the American Society of Hematology, and the American Society of Clinical Oncology. He served as the principal investigator of more than 150 clinical trials (including phase 1 and 2 studies followed by expansion cohorts) in patients with Hodgkin, non-Hodgkin lymphoma, and chronic lymphocytic leukemia including national and international multicenter studies. Prof. Zinzani is an Associate Editor of Annals of Oncology from January 2014 and he acts as a reviewer for journals such as Lancet Oncology, Journal of Clinical Oncology, Blood, Clinical Cancer Research, Cancer, Haematologica, Leukemia & Lymphoma, Leukemia, Clinical Lymphoma Myeloma. He has presented his research at more than 320 national and international meetings and has authored over 450 peer-reviewed papers in journals such as New England Journal of Medicine, Blood, Journal of Clinical Oncology, Lancet Oncology, Annals of Oncology, Oncologist, Journal Hematology & Oncology, Haematologica. His current research interest includes clinical trial methodology, prognostic factors in NHL, Hodgkin's disease, chronic lymphocytic leukemia, new drugs development, and hairy cell leukemia.



CHAIRPERSONS



**DR. ABDULAZIZ HAMADAH**  
Hematologist, Lymphoma & HSCT Unit  
Department of Medical Oncology  
Kuwait Cancer Control Center - Kuwait



**DR. AHMAD ALSAEED**  
Deputy Director  
Princess Noorah Oncology Center  
King Abdulaziz Medical City, MNGHA, Jeddah



**DR. AHMED ABSI**  
Consultant, Adult Hematology/BMT  
Princess Noorah Oncology Center  
King Abdulaziz Medical City - MNGHA, Jeddah



**DR. AHMED ALASKAR**  
Executive Director  
King Abdullah International Medical Research Center  
Hematologist Consultant & Associate Professor  
Ministry of National Guard Health Affairs - WR  
King Saud Bin Abdulaziz University for Health Sciences



**DR. AMAL ALABDALWAHAB**  
Consultant & Director of Cancer Center  
King Abdullah Medical City - Makkah



**DR. AMAL ALBEIHANY**  
Head, Hematology & Oncology Department  
Consultant, Adult Hematology & BMT  
King Fahad Hospital - Al-Madinah



**DR. AYMAN ALHEJAZI**  
Consultant, Department of Oncology  
King Abdulaziz Medical City - Riyadh



**DR. IHAB AL-HEMAIDI**  
Section Head, Adult Hematology/BMT, Oncology Center  
King Abdulaziz Medical City - MNGHA - Jeddah



**DR. JOHN APOSTOLIDIS**  
Consultant Hematologist  
Department of Adult Hematology  
& Stem Cell Transplant  
King Fahad Specialist Hospital - Dammam



**DR. KHALIL AL FARSI**  
Senior Consultant, Hematology/BMT  
Department of Hematology  
Sultan Qaboos University Hospital  
Muscat, Oman



**DR. MAHMOUD DEEB ALJURF**  
Consultant, Hematology  
King Faisal Specialist Hospital  
& Research Center - Riyadh



**DR. MAJED AL AHMADI**  
Consultant, Adult Hematology/BMT, Oncology Center  
King Abdulaziz Medical City - MNGHA - Jeddah



**DR. MOHSEN ALZAHRANI**  
Director, Saudi Stem Cell Donor Registry (SSCDR)  
Head, Stem Cell Transplant and Cellular Therapy Section  
Oncology Department  
King Abdulaziz Medical City, MNGHA - Riyadh



**DR. MOUSSAB DAMLAJ**  
Consultant Adult Hematology & HSCT  
King Abdulaziz Medical City - Riyadh



**DR. MUSA ALZAHRANI**  
Consultant & Assistant Professor, Hematology  
King Saud University - Riyadh



**PROF. REYAD DADA**  
Senior Consultant  
Hematology, Medical Oncology  
& Stem Cell Transplantation  
King Faisal Specialist Hospital  
& Research Center - Jeddah



**DR. RIAH EL-FAKIH**  
Assistant Professor, Alfaisal University  
Consultant Adult Hematology  
& Stem Cell Transplant, Oncology Center  
King Faisal Specialist Hospital  
& Research Centre - Riyadh



**DR. ROULA MUFTI**  
Consultant, Adult Medical Oncology  
Princess Noorah Oncology Center  
King Abdulaziz Medical City, MNGHA - Jeddah

**DAY**  
**1** THURSDAY  
01 April 2021

## SCIENTIFIC PROGRAM

KSA TIME	ACTIVITY TITLE	SPEAKER
19:00 – 19:15	Conference Chairman's Opening Remarks	Dr. Mubarak Almansour
	Welcome Address & Speakers Introduction	Moderators
	<b>SESSION 1 : HODGKIN LYMPHOMA</b>	Moderators: Dr. Majed Al Ahmadi & Dr. Mohsen Alzahrani
19:15 – 19:35	<b>Curing Advanced Hodgkin Lymphoma: PET Guidance and Novel Agents</b>	Dr. Joseph Connors
19:35 – 19:45	Discussion : Question & Answer	
19:45 – 20:05	<b>Relapsed/Refractory Hodgkin Lymphoma</b>	Dr. Craig Moskowitz
20:05 – 20:15	Discussion: Question & Answer	
20:15–21:00	<b>Satellite Symposium -Takeda Company</b>	Dr. Joseph Connors
	<b>"Role of Brentuximab Vedotin in Advanced Stage Newly Diagnosed HL"</b>	
	<b>SESSION 2: DIFFUSE LARGE B-CELL LYMPHOMA</b>	Moderators: Dr. Ahmed Absi & Dr. Ayman AlHejazi
21:00 – 21:30	<b>Where is the Treatment of Diffuse Large B-Cell Heading?</b>	Dr. Grzegorz Nowakowski
21:30 – 21:40	Discussion : Question & Answer	
21:40 – 22:00	<b>What is the Management Strategy for the Relapsed/Refractory DLBCL Lymphoma 2021?</b>	Dr. Laurie Sehn
22:00 – 22:10	Discussion : Question & Answer	
22:10 – 22:20	Wrap Up & Conclusion	Moderators
22:10	Closing Remarks	Dr. Mubarak Almansour

**DAY**  
**2** FRIDAY  
02 April 2021

KSA TIME	ACTIVITY TITLE	SPEAKER
14:00 – 14:10	Conference Chairman's Opening Remarks	Dr. Mubarak Almansour
14:10 – 14:20	Welcome Address & Speakers Introduction	Moderators
	<b>SESSION 3: FOLLICULAR LYMPHOMA</b>	Moderators: Dr. Ahmad Al Saeed & Dr. John Apostolidis
14:20 – 14:40	<b>Management of Follicular Lymphoma in 2021</b>	Prof. Andrew Davies
14:40 – 14:50	Discussion : Question & Answer	
14:50 – 15:10	<b>What is the Best Management Strategy for Relapsed/Refractory Follicular Lymphoma 2021?</b>	Prof. Andrew Davies
15:10 – 15:20	Discussion: Question & Answer	
15:20 – 16:05	<b>Satellite Symposium - Roche Company</b>	Dr. Riad El-Fakih
	<b>"KSA Experience in the Management of R/R DLBCL"</b>	Dr. Ali Alahmari
16:05 – 16:20	Asr Prayer Break	
	<b>SESSION 4: MANTLE CELL LYMPHOMA</b>	Moderators: Dr. Abdulaziz Hamadah & Dr. Moussab Damlaj
16:20 – 16:40	<b>Upfront Management of Mantle Cell Lymphoma in 2021</b>	Dr. Brad Kahl
16:40 – 16:50	Discussion : Question & Answer	
16:50 – 17:20	<b>Relapsed/Refractory Mantle Cell Lymphoma</b>	Prof. Michael Williams
17:20 – 17:30	Discussion : Question & Answer	
	<b>SESSION 5: CAR-T LYMPHOMA</b>	Moderator : Dr. Mahmoud Deeb AlJurf
17:30 – 17:50	<b>The Emerging Role of CAR-T in Non Hodgkin Lymphoma</b>	Prof. David Maloney
17:50 – 18:00	Discussion : Question & Answer	
18:00 – 18:10	Wrap Up & Conclusion	Moderators
18:10	Closing Remarks	Dr. Mubarak Almansour

DAY  
**3**

SATURDAY  
**03 April 2021**

KSA TIME	ACTIVITY TITLE	SPEAKER
14:00 - 14:10	Conference Chairman's Opening Remarks	Dr. Mubarak Almansour
14:10 - 14:20	Welcome Address & Speakers Introduction	Moderators
<b>SESSION 6: CLL / MZL</b>		Moderators: Dr. Ahmed Alaskar & Dr. Ihab Al Hemaidi
14:20 - 14:50	<b>How Do We Sequence Therapy for Marginal Zone Lymphomas?</b>	Prof. Pier Luigi Zinzani
14:50 - 15:00	Discussion : Question & Answer	
15:00 - 15:20	<b>The Rapidly Changing Landscape of CLL</b>	Prof. John Gribben
15:20 - 15:30	Discussion : Question & Answer	
15:30 - 15:50	<b>Satellite Symposium - Astellas Company</b> "FLT3 Mutation and AML Burden: What Clinician Should Know"	Dr. Sameer Alamoudi
<b>SESSION 7: T-CELL LYMPHOMA</b>		Moderators: Dr. Musa Fares Alzahrani & Dr. Riyadh El-Fakih
15:50 - 16:20	<b>Is it Time to Consider Chemotherapy-Free Treatments for Patients with Peripheral T-Cell Lymphoma? Yes!</b>	Prof. Owen O'Connors
16:20 - 16:30	Discussion : Question & Answer	
16:30 - 16:50	Asr Prayer Break	
16:50 - 17:10	<b>New Agents in the Treatment of Cutaneous T-Cell Lymphoma</b>	Dr. Steven Horwitz
17:10 - 17:20	Discussion : Question & Answer	
<b>SESSION 8: CENTRAL NERVOUS SYSTEM LYMPHOMA</b>		Moderators: Dr. Amal Albehainy & Prof. Reyad Dada
17:20-17:50	<b>Satellite Symposium - AstraZeneca Company</b> "Role of Acalabrutinib in MCL"	Dr. Michael Wang
17:50 - 18:10	<b>Who Should Receive Central Nervous System Prophylaxis in DLBCL?</b>	Dr. Joseph Connors
18:10 - 18:20	Discussion: Question & Answer	
18:20 - 18:40	<b>The Evolving Treatments for Primary Central Nervous System Lymphoma</b>	Dr. Andrés J. M Ferreri
18:40 - 18:50	Discussion : Question & Answer	
18:50 - 19:00	Wrap Up & Conclusion	Moderators
19:00	Closing Remarks	Dr. Mubarak Almansour

DAY  
**4**

SUNDAY  
**04 April 2021**

KSA TIME	ACTIVITY TITLE	SPEAKER
19:00 - 19:15	Conference Chairman's Opening Remarks	Dr. Mubarak Almansour
	Welcome Address & Speakers Introduction	Moderators
<b>SESSION 9: THERAPEUTIC</b>		Moderators: Dr. Amal Alabdulwahab, Dr. Khalil Farsi, & Dr. Roula Al Mufti
19:15 - 19:40	<b>New Drugs on the Horizon in Lymphoma</b>	Prof. Owen O'Connors
19:40 - 19:50	Discussion : Question & Answer	
19:50 - 20:10	<b>The Clinical Merits of Targeting PD-1/PDL1 in Non Hodgkin Lymphoma and Hodgkin Lymphoma</b>	Prof. Stephen Ansell
20:10 - 20:20	Discussion : Question & Answer	
20:20 - 20:50	<b>Satellite Symposium - MSD Company</b> "Evolution of Immuno-therapy In the Management of RR cHL Latest Updates & Clinical Practice"	Dr. Alfadel Alshaibani
20:50 - 21:10	<b>The Science Behind Targeting Immune Checkpoints in Lymphoma</b>	Prof. Stephen Ansell
21:10 - 21:20	Discussion : Question & Answer	
21:20 - 21:40	<b>Bispecific T-Cell Engager (BiTE) Antibodies in Lymphoma Malignancies</b>	Dr. Julie Vose
21:40 - 21:50	Discussion : Question & Answer	
21:50 - 22:00	Wrap Up & Conclusion	Moderators
22:00	Closing Remarks	Dr. Mubarak Almansour



**3<sup>rd</sup> INTERNATIONAL  
LYMPHOMA  
CONFERENCE**

## SPONSORS



**MSD**

**AstraZeneca**



**janssen**



**astellas**

**SANOFI**



**NOVARTIS**

**Kyowa KIRIN**

[www.ilc-jeddah.com](http://www.ilc-jeddah.com)

Organize By



**LIVE** Events Organizer  
**PRESENTATION**

شركة العرض المتاحف لتنظيم المعارض والمؤتمرات